PREDICTIVE VALUE OF FDG PET/CT IN PATIENTS WITH RELAPSE/REFRACTORY MULTIPLE MYELOMA BEFORE TREATMENT WITH ANTI‐CD38 IMMUNOTHERAPY

Introduction: Although immunotherapy with monoclonal antiCD38 antibody has improved prognosis of relapse/refractory multiple myeloma (RRMM), some patients experience early relapse with a dismal outcome. 18F-FDG PET/CT is now recommended for the visualization of disease activity in both newly diagnosed and RRMM patients. It has also been used for the prediction of survival outcome in patients treated with allogeneic stem cell transplant. This...